EUK-134 is an antioxidant compound with superoxide dismutase and catalase activity for oxidative species such as peroxynitrite, superoxide, and hydrogen peroxide.

CAY10698 (compound 1) is a potent and selective inhibitor of 12-Lipoxygenase (12-LOX) with an IC50 of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2.

For the detailed information of DTP3, the solubility of DTP3 in water, the solubility of DTP3 in DMSO, the solubility of DTP3 in PBS buffer, the animal experiment (test) of DTP3, the cell expriment (test) of DTP3, the in vivo, in vitro and clinical trial test of DTP3, the EC50, IC50,and affinity,of DTP3, Please contact DC Chemicals..

Val-Lys(Boc)-PAB is a ADC linker. Val-Lys(Boc)-PAB was used to prepare camptothecin peptide conjugates as antitumor agents (WO 2019195665). It was used as a non-​linear self-​immolative linker for reducing hydrophobicity of antibody-​drug conjugates for cancer therapy (WO 2018069375).

PI3Kδ-IN-1 is a potent, selective, and efficacious PI3Kδ inhibitor with an IC50 of 1.7 nM.

SMS2-IN-1 is a potent and highly selective sphingomyelin synthase 2 (SMS2) inhibitor with an IC50 of 6.5 nM and a Kd of 37 nM. SMS2-IN-1 shows 150-fold selectivity for SMS2 over SMS1 (IC50 of 1000 nM).

NV-5138 is an orally and centrally active small-molecule drug for the treatment of major depressive disorder (MDD). It directly and selectively activates the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway by binding to and modulating sestrin2, a leucine amino acid sensor and upstream regulatory pathway. The mTORC1 pathway is the same signaling pathway that the NMDA receptor antagonist ketamine activates in the medial prefrontal cortex (mPFC) to mediate its rapid-acting antidepressant effects. A single oral dose of NV-5138 has been found to increase mTORC1 signaling and produce synaptogenesis in the mPFC and to induce rapid antidepressant effects in multiple animal models of depression.

NSC-92828, also known as 3-Phenanthrenebutyric acid, is a Protein–protein interaction inhibitor (2P2 inhibitor or 2P2I). Protein–protein recognition is the cornerstone of multiple cellular and pathological functions. Therefore, protein–protein interaction inhibition (2P2I) is endowed with great therapeutic potential despite the initial belief that 2P2I was refractory to small-molecule intervention.

FBN33428, also known as Fmoc-​Phe-​Lys(Boc)​-​PAB; is a Hydrolyzable linker for making ADC conjugate. FBN33428 is useful for mkaing hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells. FBN33428 was first reported in WO 9813059. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available.

ZYN57939 is RNA polymerase I inhibitor for treating RNA polymerase I-​mediated diseases. ZYN57939 was first reported in CN 104177379 A 20141203 (2014). ZYN57939 showed inhibitory activity with IC50 of 0.855 μM against human HT-​29 cancer cell lines. This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available (see MedKoo Chemical Nomenclature.

 JUN04542 is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase-​dependent disorders. JUN04542 was first reported in WO 2019148044 (2019). This product has not formal name. For the convenience of scientific communication, we named it by combining its Inchi key (3 letters from the first letter of each section) with the last 5 digits of its CAS number or its molecule weight if its CAS number is not available .

HM-61713 (BI-1482694) is an orally available small molecule, mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.

HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.

HMN-176 is a stilbene derivative which inhibits mitosis without significant effect on tubulin polymerization.

HSF1A is a cell-permeable activator of heat shock transcription factor 1 (HSF1).

HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of galanin-3 receptor (Gal3).

HTHQ, which is a hydroquinone monoalkyl ether, is a potent anti-oxidative agent, even at low dose levels.

HUHS015 is a prostate cancer antigen (PCA)-1/AlkB homologue 3 (ALKBH3) inhibitor.

hVEGF-IN-1 represses human VEGF-A translation and shows antitumor activity.

Hycanthone, the most potent mutagen in a series of nine thiaxanthenones, is a potent inducer of nuclear immunoreactivity to antinucleoside antibodies in HeLa cells.

Hydroxy-Fasudil is a metabolite of Fasudil, acting as a potent Rho-kinase inhibitor and vasodilator.

Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agents.

I-191 is a novel potent, selective protease-activated receptor 2 (PAR2) antagonist with pIC50 of 7.2 in cell-based assays.

IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain.

IBMX(NSC165960; SC2964) is a competitive nonselective PDEs inhibitor with IC50 of 2-50 uM but does not inhibit PDE8 or PDE9; nonselective adenosine receptor antagonist.

IC-87114 was the first isoform-selective PI3K inhibitor. p110δ(IC50 = 0.13 μM) vs. p110α(IC50 = 200 μM), p110β(IC50 = 16 μM) and p110γ(IC50 = 61 μM).

ICA 069673 is a potassium channel opener with selective action for KCNQ2 and KCNQ3 (EC50=0.69 μM). No meeasurable activity was displayed over a variety of cardiac ion channels.

Icariside I is a metabolite of Icarlin, which could regulate bone remodeling and is recognized as an effective agent for the treatment of osteoporosis.

Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.

AEOL-10150 pentachloride is a metalloporphyrin catalytic antioxidant and is a superoxide dismutase mimetic, and protects lungs from radiation-induced injury[1].